Kornimate/medical-research-clean huggingface dataset:
a study of thymopentin effects on hiv-1 infectivity of blood mononuclear cells and semen in hiv infected patients

Conditions: HIV Infections

Summary: examine the ability of timunox (thymopentin) to reduce the amount and/or frequency of virus isolation. examine the ability of thymopentin to stimulate the immune system and alter the clinical findings in patients infected with hiv who do not yet have aids.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * aerosolized pentamidine. patients must have the following: * seropositive for hiv-1 (elisa assay) confirmed by western blot. * hiv-1 p24 antigen must be detected in supernatant fluids from co-cultures of patients' pbmc on two separate occasions. * voluntarily sign consent. * patients with hiv "wasting syndrome" are allowed. prior medication: allowed: * aerosolized pentamidine. exclusion criteria co-existing condition: patients with the following are excluded: * aids as defined by the cdc. * significant hepatic disease. * thrombocytopenia. * hypersensitivity to thymopentin. * hemophilia a or b or other hematologic disorders requiring current or previous administration of blood products. * abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry. patients with the following are excluded: * aids as defined by the cdc. * significant hepatic disease. * thrombocytopenia. * hypersensitivity to thymopentin. * hemophilia a or b or other hematologic disorders requiring current or previous administration of blood products. * abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry. prior medication: excluded within 30 days of study entry: * immunomodulatory or experimental therapy. * excluded within 90 days of study entry: * zidovudine (azt). intravenous drug abuse.

Keywords: semen thymopentin leukocytes, mononuclear aids-related complex
dt-9081 study in participants with advanced, recurrent or metastatic solid tumours

Conditions: Solid Tumor, Adult

Summary: this is a phase 1, multicentre, open-label, dose-escalation study to determine a recommended phase 2 dose (rp2d) of dt-9081, followed by an expansion study of dt-9081 in participants with advanced, recurrent or metastatic solid tumours

this first-in-human phase 1, multicentre, open label study is evaluating the safety, tolerability, pharmacokinetics (pk), pharmacodynamics (pd), and preliminary efficacy of dt-9081 in adult patients with advanced, recurrent or metastatic solid tumours who failed standard of care therapies. this phase 1 study consists of 2 parts. the first part is a dose-escalation using a modified 3+3 design with up to 8 dose escalation cohorts at increasing levels. the dose-escalation part aims at determining the recommended phase 2 dose. the second part is an expansion to validate the dose/schedule of administration as well as to assess preliminary efficacy of dt-9081. patients will be dosed orally once daily. the schedule might be adjusted in case of toxicities.

Eligibility criteria:
inclusion criteria: * participants must have a histologically or cytologically confirmed advanced solid tumour that is locally advanced (i.e., not eligible for curative surgery or radiotherapy), recurrent or metastatic, and who have failed or are ineligible for standard of care therapies. * participants must be ≥18 years of age. * participants must have measurable disease per recist v1.1. lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. * eastern cooperative oncology group (ecog) performance status 0 or 1. * participants must have adequate organ function. exclusion criteria: * participants using drugs interfering with the cox-2 pathways or prohibited drugs. * participants with unresolved aes from previous anti-cancer therapies of grade ≥ 2 with exception of alopecia. participants with grade ≤ 2 neuropathy may be eligible. * participants who underwent major surgery or significant traumatic injury within 4 weeks prior to cycle 1 day 1 who have not recovered adequately from any aes and/or complications from the intervention prior to starting study drug. * participants who have received prior radiotherapy within the last 4 weeks before start of study drug treatment (limited field palliative radiotherapy within 2 weeks). * participants who have already received ep4r antagonist in an investigational trial.

Keywords: advanced cancer immuno-oncology
a phase ii study of pulse reduced dose rate radiation therapy with bevacizumab

Conditions: Glioma

Summary: to determine the efficacy of pulse reduced dose rate (prdr) radiation when given in 27 fraction over 5.5 weeks with concurrent bevacizumab followed by adjuvant bevacizumab until time of progression in patients with recurrent high grade gliomas (grade iii and grade iv). patients will be placed in 1 of 4 groups based on their histologic diagnosis and prior exposure to bevacizumab.


Eligibility criteria:
inclusion criteria: * histologically or molecularly confirmed grade 3 or 4 glioma, idh mutant or wildtype, as defined by the 2021 who guidelines * recurrent disease based on combination of clinical, imaging or histologic confirmation * must have previously received radiation and temozolomide to treat their glioma * bevacizumab naive patients must be \> 5 months post completion of initial radiation therapy * bevacizumab exposed patients must be \> 3 months post completion of initial radiation therapy * age must be \>18years, kps must be greater than 60 * hematology, chemistry and a urinalysis must meet protocol specified criteria exclusion criteria: * pregnant or breastfeeding * uncontrolled hypertension (\>160/90mmhg) * prior malignancy unless treated \>1 year prior to study and have been without treatment and disease free for 1 yr * active second malignancy unless non-melanoma skin cancer or cervical cancer in situ

Keywords: glioblastoma anaplastic glioma
the impact of actos treatment of diabetes on glucose transporters in muscle

Conditions: Diabetes Type 2

Summary: subjects with type 2 diabetes will be treated with actos or placebo for eight weeks and needle biopsies of muscle will quantify changes in any of seven different glucose transport proteins in muscle.

twelve subjects with type 2 diabetes, with fair control on oral medication, will be recruited to participate in a randomized, double-blind, placebo-controlled study of the impact on muscle glucose transporter expression of the addition of the insulin-sensitizing agent, pioglitizone (takeda pharmaceuticals). therapy with the active drug will be at 30 mg daily. the other oral medications will be adjusted downward if hypoglycemia occurs. glycemic control will be monitored by at least twice daily home blood glucose monitoring, weekly telephone contacts, and follow-up visits to the etsu/vamc clinical research unit (cru) every two weeks. during the eight weeks of therapy, subjects will be instructed to maintain their weight and keep their dietary and exercise regimens unchanged. muscle biopsies will be obtained before and at the end of eight weeks of therapy. specimens will be assayed for glut1, glut3, glut4, glut5, glut8, glut11, and glut12 mrna and protein content and the subcellular distribution of these proteins as described below. peroxisome proliferator-activated receptor gamma (ppargamma), a member of the ligand-activated nuclear hormone receptor superfamily (14), will be quantified in these specimens by immunoblot as described below. this study design involving a randomized, double-blinded, placebo-controlled treatment regimen is needed to control for confounding variables causing changes in glucose transporter expression that may be erroneously attributed to the drug. these potential variables include close contact with the diabetes management team resulting in improved compliance with diet, exercise, medication, and monitoring and thus better glycemic control, weight loss, or improved fitness.

Eligibility criteria:
inclusion criteria: * diabetes, type 2 * hba1c less than 8.5 exclusion criteria: * insulin therapy * renal insufficiency * clinically apparent coronary disease

Keywords: muscle glucose transporters glut4 glut5 actos
gastrointestinal manifestations among patients with covid19

Conditions: Covid19

Summary: many patients with confirmed infection with covid-19 suffer from different symptoms and signs of gastrointestinal symptoms

many patients with covid1-9 infection experienced many intestinal symptoms mainly abdominal pain, vomiting, and diarrhea. this study aimed to assess the frequency of git manifestations among patients with covid-19 and its impact on the outcome

Eligibility criteria:
inclusion criteria: * all patients with covid19 exclusion criteria: * patient refusal to participate in the study
magnetic resonance imaging (mri) of pulp regeneration

Conditions: Pulp Necroses; Periapical Lesion; Regeneration

Summary: the present study was conducted to test whether pulp-like tissue can be regenerated in mature teeth with closed apex? and whether the size of the apical diameter affects the success of reps? and whether magnetic resonance imaging (mri) can be used to quantitatively assess the vitality of the regenerated pulp-like tissue.

regenerative endodontic procedures via blood clot were done on 18 mature anterior necrotic teeth with periapical lesions. the teeth were randomly assigned into two groups according to the size of the apical diameter of the rotary files used for instrumentation. in the test group, rotary instrumentation was done using pro-taper next till size x3, while in the control group, instrumentation was done till size x5. calcium hydroxide was used as an intracanal medication for 1-2 weeks. calcium hydroxide was then washed away using 1.5%naocl, followed by induction of blood using pre-curved k-fi;e #25 2mm past the radiographic apex. biodentine was then used as a cervical plug over the blood clot followed by resin-modified glass ionomer cement and composite resin as coronal restoration. mri was used to assess the vitality of the regenerated pulp-like tissue, where the signal intensity of the regenerated pulp-like tissue was measured after 3,6 and 12 months follow up and compared to the normal contralateral teeth. in addition, sensibility tests using cold test and electric pulp testing were used to assess vitality of regenerated pulp-like tissue after 3,6,9 and 12 months. cone beam computed tomography (cbct) was also used to assess the healing of the periapical lesion after 12 months.

Eligibility criteria:
inclusion criteria * upper anterior mature teeth with single canals. * necrotic teeth * presence of periapical lesion. exclusion criteria: * presence of systemic diseases. * presence of stainless steel wires o brackets * vital immature teeth with open apex

Keywords: mature teeth necrotic teeth reps biodentine mri cbct
quebec registry for atypical femur fractures

Conditions: Atypical Femur Fracture

Summary: bisphosphonates are recommended as first-line agents to reduce fracture risk in patients with osteoporosis and have in general an excellent safety profile. however, recent reports have noted that prolonged use of bisphosphonates may be associated with rare but serious adverse effects, namely atypical femur fractures (aff), an atraumatic subset of subtrochanteric and diaphyseal fractures. the overarching aim of this project is to contribute to the characterization of clinical, biomechanical, radiological and genetic predictors of aff, associated or not with bisphosphonate and-or denosumab therapy. aff arise on the lateral (external) aspect of the subtrochanteric and diaphyseal regions of the femur, regions subjected to high mechanical loads. because of this unique distribution, the investigators hypothesis is that patients with aff demonstrate specific geometrical variations of their femur whereby baseline tensile forces applied to the lateral cortex are higher and might favour the appearance of these rare stress fractures. measurements to investigate these geometric variations with be calculated from 3d images reconstructed using scans procured using the eos® low irradiation 2d-3d x-ray scanner.


Eligibility criteria:
inclusion criteria: * age 45 years and older * men and women from quebec who sustain (or have sustained) an aff (complete or incomplete), as defined by the american society of bone and mineral research (asbmr) international task force on affs (shane e et al j bone miner res 2014;29:1-24) exclusion criteria: * inability to consent * disorders of bone metabolism other than osteoporosis * active cancer * life expectancy less than 12 months.

Keywords: femoral fractures subtrochanteric fractures osteoporotic fractures fractures, spontaneous stress fractures bone fractures hip fractures osteoporosis
a study of fc084csa in combination of tislelizumab in patients with advanced malignant solid tumors

Conditions: Advanced Malignant Solid Tumors

Summary: the goal of this clinical trial is to learn the safety, tolerability, pharmacokinetic characteristics and efficacy of fc084csa in combination with tislelizumab in patients with advanced malignant solid tumors.

the study includes two phases. phase ib adopts a "3+3" dose escalation design to assess safety and tolerability of increasing dose levels of fc084csa in combination of fixed dose of tislelizumab. phase iia is the dose expansion phase to further observe the preliminary effectiveness of the recommended phase 2 dose of fc084csa in combination of tislelizumab.

Eligibility criteria:
inclusion criteria: 1. aged 18 to 75 years old male and female. 2. phase ib: patients with histologically or cytologically diagnosed solid tumors who have failed standard therapy; phase iia: patients with histologically or cytologically confirmed stage iiib/iiic and stage iv nsclc which surgery or radiotherapy cannot be performed. 3. no known sensitizing mutations or other actionable oncogenes with approved therapies if available. 4. prior pd-1/pd-l1 inhibitor combined with platinum-containing therapy failed; 5. according to recist 1.1, there is at least one measurable lesion. 6. ecog performance status 0-1. 7. major organs are functioning well. exclusion criteria: 1. not recovered from the adverse reactions caused by previous anti-tumor treatments (≥ctcae grade 1). 2. received anti-tumor therapy within 4 weeks before enrollment. 3. participated in other clinical trials within 4 weeks before enrollment and used clinical investigational drugs during this period. 4. have undergone surgery within 4 weeks before enrollment, and the investigator believes that the patient's state has not recovered to the point where the study can be started. 5. patients with ascites (ascites), pleural effusion (pleural effusion) or pericardial effusion that cannot be controlled by drainage or other methods. 6. central nervous system metastases with clinical symptoms. 7. with any situations that the researcher considers inappropriate to participate in this research.
cognitive disorders and brain pulse

Conditions: Neurocognitive Disorders

Summary: following an initial consultation with a memory, resources and research centre (mrrc) doctor, a day hospital may be prescribed to carry out an assessment of cognitive disorders. patients are then usually followed up in consultation at least once a year, in the framework of a new day hospital and/or consultations with a mrrc doctor.

patients will be included at the time of the day hospital assessment. all patients received in the day hospital of the mrrc of tours will be offered the tpi examination. the patients included will be followed up for a period of 5 years and the tpi examination will be repeated according to the same modalities, as part of their follow-up at the mrrc and/or in the context of a new day hospital if necessary.

Eligibility criteria:
inclusion criteria: * patient benefiting from a day hospital at the mrrc of the chu of tours for assessment of cognitive functions exclusion criteria: * refusal of tpi ultrasound examination * patients who opposed to data processing * patients under judicial protection

Keywords: brain pulse ultrasound
a study of the efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors

Conditions: Well-differentiated Pancreatic Neuroendocrine Tumor

Summary: the purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.

this study is being conducted to meet regulatory post-marketing commitments.

Eligibility criteria:
inclusion criteria: * histologically or cytologically proven diagnosis of well-differentiated pancreatic neuroendocrine tumor (according to world health organization \[who 2000\] classification). * disease progression within 12 months prior to study enrollment. * disease that is not amenable to surgery, radiation, or combined modality therapy with curative intent. exclusion criteria: * patients with poorly differentiated pancreatic neuroendocrine tumors (according to who 2000 classification). * prior treatment with any tyrosine kinase inhibitors, anti vascular endothelial growth factor (vegf) angiogenesis inhibitors, non vegf targeted angiogenesis inhibitors, or mammalian target of rapamycin (mtor) inhibitors.

Keywords: neuroendocrine tumors adenoma islet cells carcinoma islet cells pancreatic neoplasms angiogenesis inhibitors sunitinib neoplasms carcinoma adenoma
effect of artıfıcıal intellıgence based mobıle vırtual assıstant

Conditions: Diabetes

Summary: aim: this study was conducted experimentally to examine the effect of artificial intelligence-based mobile virtual assistant developed for individuals with diabetes on cost, hospitalization rate, self-care and hypoglycemia. methods: the research is multi-stage and designed as three stages in itself. according to this; development of the mobile application in the first and second stages and adding artificial intelligence to the application as a project; in the third stage, it was planned to examine the effect of the application on the variables and scales. the data of the study were collected between june 2022 and june 2023 in the endocrinology polyclinic of two private hospitals in izmir and a diabetes association where individuals with diabetes were registered. power 0.80 was determined by using ncss pas statistical software from the population of the research; the minimum number of samples to be included in the study was calculated as n:122 and they were divided into two as intervention and control groups by randomization. the research sample was carried out as intervention (n:60) and control (n:60) lastly due to death and cost. five data collection tools were used, namely "individual introduction form", "diabetes self-care scale", "hypoglycemia confidence scale", "mobile application opinion form" and "cost table". an artificial intelligence-based mobile virtual assistant application was applied to the individuals with diabetes in the intervention group, and the data were collected three times, at the 0th, 6th and 12th months, and the costs were recorded. the standard outpatient trainings, which are currently applied, continued to be given to individuals with diabetes in the control group, the data were collected twice, at the beginning (0. month) and 12. months, and the costs were recorded. in the evaluation of the data, number, percentage, arithmetic mean, standard deviation, minimum and maximum median were calculated. among the variables, chi-square, kruskal wallis, mann whitney u test and t test were used.


Eligibility criteria:
inclusion criteria: * having been diagnosed with type 1 and type 2 diabetes at least six months ago, according to the criteria of the american diabetes association (ada), * using insulin for at least six months, * being between the ages of 18- 65, * being able to read and write and speak turkish, * having an android phone and being able to use mobile applications, * to volunteer to participate in the study. exclusion criteria:

Keywords: diabetes mobile application artificial intelligence self-care hospitalization cost
a study comparing different dosing regimens of ixekizumab (ly2439821) in participants with moderate to severe plaque psoriasis

Conditions: Plaque Psoriasis

Summary: the main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.

the purpose of this study is to evaluate both the safety and efficacy of ixekizumab dosing regimens. there are 3 study periods: screening period, blinded treatment dosing period, and post-treatment follow-up.

Eligibility criteria:
inclusion criteria: * present with chronic plaque psoriasis for at least 6 months prior to enrollment * at least 10% bsa of psoriasis at screening and at enrollment * spga score of at least 3 and pasi score of at least 12 at screening and at enrollment * candidates for phototherapy and/or systemic therapy * participant must agree to use reliable method of birth control during the study; women must continue using birth control for at least 12 weeks after stopping treatment exclusion criteria: * predominant pattern of pustular, erythrodermic, or guttate forms of psoriasis * history of drug-induced psoriasis * cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study * received systemic non-biologic psoriasis therapy or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to enrollment * concurrent or recent use of any biologic agent * have participated in any study with ixekizumab * received a live vaccination within 12 weeks prior to enrollment * serious disorder or illness other than psoriasis * ongoing or serious infection within the last 12 weeks or evidence of tuberculosis * major surgery within 8 weeks of baseline, or will require surgery during the study * breastfeeding or nursing (lactating) women